HWHG(SH:600079) Xin Lang Cai Jing·2025-11-17 02:13Core Viewpoint - Renfu Pharmaceutical's stock has experienced a decline of 11.71% year-to-date, with a recent drop of 2.02% on November 17, 2023, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Renfu Pharmaceutical reported a revenue of 17.883 billion yuan, a year-on-year decrease of 6.58%, while the net profit attributable to shareholders was 1.689 billion yuan, reflecting a year-on-year growth of 6.22% [2]. - Cumulative cash dividends since the company's A-share listing amount to 3.113 billion yuan, with 1.779 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Renfu Pharmaceutical increased to 69,400, a rise of 38.71%, while the average circulating shares per person decreased by 27.91% to 22,222 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 42.1832 million shares, a decrease of 1.3907 million shares compared to the previous period [3].